Table 1. Summary of the mean efficacy results from rAceyCP1/Alhydrogel vaccine trials and comparison to clinical hookworm antigen candidates.
| vaccine group | compared to adjuvant | Change in burden | Change in FEC | Change in weight (g) | Change in Hg (g/dL) |
|---|---|---|---|---|---|
| rAceyCP1_1—all | Alhydrogel | -30.7%* | -46.7%* | +7.6** | -0.1 |
| rAceyCP1_1—R | Alhydrogel | -53.8%** | -65.5%* | +9.6* | +2.2 |
| rAceyCP1_2—all | Alhydrogel | -18.8% | -25.7%* | +2.8 | +0.4 |
| rAceyCP1_2—R | Alhydrogel | -40.1%** | -53.7%*** | +6.0** | +2.0 |
| rAcanAPR1—Ra | ASO3 | -33.0% | -70.0%* | n/a | +3.0* |
| rAcanGST1—Rb | ASO3 | -39.4% | -32.3% | n/a | n/a |
* P < 0.05.
** P < 0.01.
*** P < 0.001; No asterisk indicated not significant at P<0.05.
aLoukas et al. [27] vaccine trial in beagles; only published trial that thoroughly reported efficacy (hookworm burden, fecal egg count [FEC] and a measure of clinical pathology), and immunogenicity for APR1. rAcanAPR1 gave 100% responder (R) rate with serum IgG2 titer of ~121,500 and IgG1 titer of ~13,500.
bZhan et al. [26] vaccine trial in beagles; only published trial that reported multiple measures of protection (hookworm burden and FEC), and immunogenicity for GST1. rAcanGST1 gave 100% responder rate with serum IgG2 titer of ~40,500 and IgG1 titer of ~13,500. For comparisons, rAceyCP1 responders gave serum IgG titers of only 4,000–10,000 in trial 1, and only 2,000–20,000 in trial 2. Additional abbreviations: Hg: Hemoglobin; R, responders; NR, nonresponders; Acan, A. caninum.